Beckman Coulter Slapped With Class Action Suit Over Its Troponin Kits

The suit accuses the company and certain of its officers of violating Securities and Exchange Commission rules by failing to disclose that it modified its troponin test kits without "proper FDA approval," among other allegations.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.